Popis: |
Background: HIV infection has reached pandemic proportions ever since the first case was reported in 1981. Now, it continues to be the most important communicable disease in India with its associated high morbidity, mortality and treatment costs. With the introduction of highly active antiretroviral therapy, people with HIV infection now live longer. And the major contributors to morbidity and mortality are drug toxicities and metabolic derangements due to HAART, not the opportunistic infections. Dyslipidemia is one such metabolic derangement which occurs either as an adverse effect of ART drugs or due to HIV infection per se. This study was undertaken to address the second issue, as the data from India is limited. Methods: 80 newly detected HIV patients who were naive to antiretroviral drugs and who did not have exclusion criteria like prior diabetes mellitus, thyroid disease, hepatitis, pregnancy etc. were selected randomly and enrolled into the study over a year. A baseline complete hemogram with CD4 cell count and all necessary biochemical tests were done. The patients were grouped according to WHO staging. 80 age and sex matched healthy controls were also enrolled during the same period and they were also subjected to similar investigations. The various lipid parameters were analysed and compared between two groups as well as among patients with different WHO stages and CD4 lymphocyte counts. Results: 80 cases and 80 controls who were age and sex matched were enrolled. Mean BMI was significantly less in cases. Among cases, 72 patients (90%) had CD4 count |